The effects of N-terminal part modification of arginine vasopressin analogues with 2-aminoindane-2-carboxylic acid: A highly potent V2 agonist

Journal of Medicinal Chemistry

Volumn 50, Issue 12, 2007, Pages 2926-2929

  Kowalczyk, Wioleta ^a   Sobolewski, Dariusz ^a   Prahl, Adam ^a   Derdowska, Izabela ^a   Borovičková, Lenka ^b   Slaninová, Jiřina ^b   Lammek, Bernard ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOINDANE 2 CARBOXYLIC ACID; ARGIPRESSIN DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; PHENOXYBENZAMINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULE; NONHUMAN; PHYSICAL CHEMISTRY; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTIDIURETIC AGENTS; ARGININE VASOPRESSIN; BLOOD PRESSURE; CARBOXYLIC ACIDS; FEMALE; PROTEIN CONFORMATION; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP; UTERINE CONTRACTION;

EID: 34250830349     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070174s     Document Type: Article

References (23)

1. Jard, S.; Barberis, C.; Audigier, S.; Tribollet, E. Neurohypophyseal hormone receptor systems in brain periphery. Prog. Brain Res. 1987, 72, 173-187.
2. Jard, S. Mechanisms of action of vasopressin antagonists. Kidney Int. 1988, 34, 38-42.
3. 3 pituitary vasopressin receptor: Ligand binding profile and density-dependent signaling pathways. Endocrinology 1997, 138, 4109-4122.
4. Kam, P. C. A.; Williams, S.; Yoong, F. F. Y. Vasopressin and terlipressin: Pharmacology and its clinical relevance. Anaesthesia 2004, 59, 993-1001.
5. Lebl, M.; Jošt, K.; Brtník, F. Tables of Analogs in Handbook of Neurohypophyseal Hormone Analogs; Jošt, K., Lebl, M., Brtník, F., Eds.; CRC Press Inc.: Boca Raton, FL, 1987; Vol. II, Part 2, pp 127-267.
6. Manning, M.; Bańkowski, K.; Sawyer, W. H. Selective agonists and antagonists of vasopressin. In Vasopressin; Gash, D. M., Boer, G. J., Eds.; Plenum Press: New York, 1987; pp 335-368.
7. Manning, M.; Sawyer, W. H. Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J. Recept. Res. 1993, 13, 195-214.
8. Hruby, V. J.; Smith, C. W. Structure-activity relationship of neurohypophysical peptides. In The Peptides; Smith, C. W., Eds.; Academic Press: Orlando, FL, 1987; Vol. 8, pp 77-207.
9. Laszlo, F. A.; Laszlo, F.; De Wied, D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol. Rev. 1991, 43, 73-108.
10. Lammek, B.; Czaja, M.; Derdowska, I.; Rekowski, P.; Trzeciak, H. I.; Sikora, P.; Szkrobka, W.; Stojko, R.; Kupryszewski, G. Influence of L-naphthylalanine in position 3 of AVP and its analogues on their pharmacological properties. J. Pept. Res. 1997, 49, 261-268.
11. Sobocińska, M.; Łempicka, E.; Konieczna, E.; Derdowska, I.; Lammek, B.; Melhem, S.; Kozik, W.; Janecka, J.; Janecki, M.; Trzeciak, H. I. Analogues of arginine vasopressin modified in position 2 or 3 with naphthylalanine: Selective antagonists of oxytocin in vitro. J. Pharm. Pharmacol. 2000, 52, 1105-1112.
12. Derdowska, I.; Prahl, A.; Kowalczyk, W.; Janecki, M.; Melhem, S.; Trzeciak, H. I.; Lammek, B. Influence of enantiomers of 1-napthylalanine in position 2 of AVP and dAVP on their pharmacological properties. Eur. J. Med. Chem. 2005, 40, 63-68.
13. Jastrzȩbska, B.; Derdowska, I.; Kowalczyk, W.; Machova, A.; Slaninová, J.; Lammek, B. Influence of 1-aminocyclohexane-1-carboxylic acid in position 2 or 3 of AVP and its analogues on their pharmacological properties. J. Pept. Res. 2003, 62, 70-77.
14. 2 agonists of arginine vasopressin. J. Med. Chem. 2004, 47, 6020-6024.
15. Kowalczyk, W.; Prahl, A.; Dawidowska, O.; Derdowska, I.; Sobolewski, D.; Hartrodt, B.; Neubert, K.; Slaninova, J.; Lammek, B. The influence of 1-aminocyclopentane-1-carboxylic acid at position 2 or 3 of AVP and its analogues on their pharmacological properties. J. Pept. Sci. 2005, 11, 584-588.
16. Bodanszky, M.; Bodanszky, A. The Practice of Peptide Synthesis; Springer-Verlag: Berlin, Germany, 1984; Vol. 83.
17. Stewart, J. M. Solid Phase Peptide Synthesis; Pierce Chem. Corp.: Rockford, IL, 1984.
18. Holton, P. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. Br. J. Pharmacol. 1948, 3, 328-334.
19. Rudinger, J.; Krejci, I. Dose-response relations for some synthetic analogues of oxytocin, and the mode of action of oxytocin on the isolated uterus. Experientia 1962, 18, 585-588.
20. Dekanski, J. The quantitative assay of vasopressin. Br. J. Pharmacol. 1952, 7, 567-572.
21. Slaninová, J. Fundamental Biological Evaluation. In Handbook of Neurohypophyseal Hormone Analogs; Jošt, K., Lebl, M., Brtník, F., Ed.; CRC Press Inc.: Boca Raton, Florida, 1987; Vol. I, Part 2, pp 83-107.
22. Burn, H. J.; Finney, D. J.; Goodwin, L. G. Biological Standardization, 2nd edition; Oxford University Press: London, 1950; p 187.
23. Vávra, I.; Machová, A.; Krejčí, I. Antidiuretic action of 1-deamino-8-D-arginine vasopressin in unanesthetized rats. J. Pharmacol. Exp. Ther. 1974, 188, 241-247.